Urinary Fibronectin in Diagnosis and Follow‐up of Patients with Urinary Bladder Cancer

P. ‐U MALMSTRÖM, A. LARSSON, S. JOHANSSON

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Summary— The levels of fibronectin in urine from 106 patients with urinary bladder cancer, from 13 patients with benign urological disease and from 24 healthy control individuals were determined by an enzyme‐linked immunosorbent assay (ELISA). The fibronectin levels in urine from patients with bladder cancer were higher than in patients with benign urothelial disease and in healthy controls. In 9 patients with bladder cancer, sampling was done both pre‐ and post‐operatively. In these cases the fibronectin levels after operation were significantly lower than they had been before. Among 14 patients treated with BCG intravesically for superficial bladder tumours, those with complete remission of disease had less urinary fibronectin than those who did not respond to treatment. The data suggest that urinary fibronectin may be a useful marker for detecting urinary bladder cancer and for selecting patients for BCG treatment.

Original languageEnglish (US)
Pages (from-to)307-310
Number of pages4
JournalBritish Journal of Urology
Volume72
Issue number3
DOIs
StatePublished - Sep 1993

Fingerprint

Fibronectins
Urinary Bladder Neoplasms
Mycobacterium bovis
Urine
Urologic Diseases
Immunosorbents
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Urinary Fibronectin in Diagnosis and Follow‐up of Patients with Urinary Bladder Cancer. / MALMSTRÖM, P. ‐U; LARSSON, A.; JOHANSSON, S.

In: British Journal of Urology, Vol. 72, No. 3, 09.1993, p. 307-310.

Research output: Contribution to journalArticle

MALMSTRÖM, P. ‐U ; LARSSON, A. ; JOHANSSON, S. / Urinary Fibronectin in Diagnosis and Follow‐up of Patients with Urinary Bladder Cancer. In: British Journal of Urology. 1993 ; Vol. 72, No. 3. pp. 307-310.
@article{379aa261e216470faca975b41e99aa78,
title = "Urinary Fibronectin in Diagnosis and Follow‐up of Patients with Urinary Bladder Cancer",
abstract = "Summary— The levels of fibronectin in urine from 106 patients with urinary bladder cancer, from 13 patients with benign urological disease and from 24 healthy control individuals were determined by an enzyme‐linked immunosorbent assay (ELISA). The fibronectin levels in urine from patients with bladder cancer were higher than in patients with benign urothelial disease and in healthy controls. In 9 patients with bladder cancer, sampling was done both pre‐ and post‐operatively. In these cases the fibronectin levels after operation were significantly lower than they had been before. Among 14 patients treated with BCG intravesically for superficial bladder tumours, those with complete remission of disease had less urinary fibronectin than those who did not respond to treatment. The data suggest that urinary fibronectin may be a useful marker for detecting urinary bladder cancer and for selecting patients for BCG treatment.",
author = "MALMSTR{\"O}M, {P. ‐U} and A. LARSSON and S. JOHANSSON",
year = "1993",
month = "9",
doi = "10.1111/j.1464-410X.1993.tb00723.x",
language = "English (US)",
volume = "72",
pages = "307--310",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Urinary Fibronectin in Diagnosis and Follow‐up of Patients with Urinary Bladder Cancer

AU - MALMSTRÖM, P. ‐U

AU - LARSSON, A.

AU - JOHANSSON, S.

PY - 1993/9

Y1 - 1993/9

N2 - Summary— The levels of fibronectin in urine from 106 patients with urinary bladder cancer, from 13 patients with benign urological disease and from 24 healthy control individuals were determined by an enzyme‐linked immunosorbent assay (ELISA). The fibronectin levels in urine from patients with bladder cancer were higher than in patients with benign urothelial disease and in healthy controls. In 9 patients with bladder cancer, sampling was done both pre‐ and post‐operatively. In these cases the fibronectin levels after operation were significantly lower than they had been before. Among 14 patients treated with BCG intravesically for superficial bladder tumours, those with complete remission of disease had less urinary fibronectin than those who did not respond to treatment. The data suggest that urinary fibronectin may be a useful marker for detecting urinary bladder cancer and for selecting patients for BCG treatment.

AB - Summary— The levels of fibronectin in urine from 106 patients with urinary bladder cancer, from 13 patients with benign urological disease and from 24 healthy control individuals were determined by an enzyme‐linked immunosorbent assay (ELISA). The fibronectin levels in urine from patients with bladder cancer were higher than in patients with benign urothelial disease and in healthy controls. In 9 patients with bladder cancer, sampling was done both pre‐ and post‐operatively. In these cases the fibronectin levels after operation were significantly lower than they had been before. Among 14 patients treated with BCG intravesically for superficial bladder tumours, those with complete remission of disease had less urinary fibronectin than those who did not respond to treatment. The data suggest that urinary fibronectin may be a useful marker for detecting urinary bladder cancer and for selecting patients for BCG treatment.

UR - http://www.scopus.com/inward/record.url?scp=0027184092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027184092&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.1993.tb00723.x

DO - 10.1111/j.1464-410X.1993.tb00723.x

M3 - Article

C2 - 8220992

AN - SCOPUS:0027184092

VL - 72

SP - 307

EP - 310

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -